Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

58 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.
Stangier J, Su CA, Roth W. Stangier J, et al. J Int Med Res. 2000 Jul-Aug;28(4):149-67. doi: 10.1177/147323000002800401. J Int Med Res. 2000. PMID: 11014323 Clinical Trial.
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J. Glund S, et al. Among authors: stangier j. Lancet. 2015 Aug 15;386(9994):680-90. doi: 10.1016/S0140-6736(15)60732-2. Epub 2015 Jun 15. Lancet. 2015. PMID: 26088268 Clinical Trial.
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
Stangier J, Stähle H, Rathgen K, Fuhr R. Stangier J, et al. Clin Pharmacokinet. 2008;47(1):47-59. doi: 10.2165/00003088-200847010-00005. Clin Pharmacokinet. 2008. PMID: 18076218 Clinical Trial.
Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
Glund S, Coble K, Gansser D, Stangier J, Hoermann K, Pollack CV, Reilly P. Glund S, et al. Among authors: stangier j. J Thromb Haemost. 2019 Aug;17(8):1319-1328. doi: 10.1111/jth.14476. Epub 2019 Jun 18. J Thromb Haemost. 2019. PMID: 31050868 Free PMC article. Clinical Trial.
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.
Yasaka M, Ikushima I, Harada A, Imazu S, Taniguchi A, Norris S, Gansser D, Stangier J, Schmohl M, Reilly PA. Yasaka M, et al. Among authors: stangier j. Res Pract Thromb Haemost. 2017 Aug 5;1(2):202-215. doi: 10.1002/rth2.12029. eCollection 2017 Oct. Res Pract Thromb Haemost. 2017. PMID: 30046691 Free PMC article.
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Norris S, Ramael S, Ikushima I, Haazen W, Harada A, Moschetti V, Imazu S, Reilly PA, Lang B, Stangier J, Glund S. Norris S, et al. Among authors: stangier j. Br J Clin Pharmacol. 2017 Aug;83(8):1815-1825. doi: 10.1111/bcp.13269. Epub 2017 Apr 6. Br J Clin Pharmacol. 2017. PMID: 28230262 Free PMC article. Clinical Trial.
Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
Glund S, Reilly P, van Ryn J, Stangier J. Glund S, et al. Among authors: stangier j. Clin Pharmacokinet. 2017 Feb;56(2):209-210. doi: 10.1007/s40262-016-0493-1. Clin Pharmacokinet. 2017. PMID: 28028767 Free PMC article. No abstract available.
Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers.
Schmohl M, Glund S, Harada A, Imazu S, De Smet M, Moschetti V, Ramael S, Ikushima I, Grünenfelder F, Reilly P, Stangier J. Schmohl M, et al. Among authors: stangier j. Thromb Haemost. 2017 Jan 26;117(2):269-276. doi: 10.1160/TH16-05-0385. Epub 2016 Dec 1. Thromb Haemost. 2017. PMID: 27904905 Clinical Trial.
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J. Reilly PA, et al. Among authors: stangier j. Am J Emerg Med. 2016 Nov;34(11S):26-32. doi: 10.1016/j.ajem.2016.09.050. Epub 2016 Sep 28. Am J Emerg Med. 2016. PMID: 27707528 Free article. Review.
An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery.
Eriksson BI, Mikuska Z, Feuring M, Amiral J, Haertter S, Stangier J, Nehmiz G, Weitz JI. Eriksson BI, et al. Among authors: stangier j. Thromb Res. 2016 Aug;144:158-64. doi: 10.1016/j.thromres.2016.06.017. Epub 2016 Jun 16. Thromb Res. 2016. PMID: 27352238 Clinical Trial.
58 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback